Juno Therapeutics Signs License and Clinical Supply Agreement with Oxford Biomedica for LentiVector Platform
Shots:
- Oxford Biomedica to receive $10M up front in cash- ~$86M as development and regulatory milestones- ~ $131M as commercial milestones and royalties on sales of products developed by Juno Therapeutics utilizing the LentiVector platform
- Oxford Biomedica will also receive payments from process development and scale-up projects as well as relating to the GMP manufacture of lentiviral vectors for use in clinical trials. Additionally- Juno gets access to Oxford’s new 7-800 m2 manufacturing centre- OxBox and allow it to initiate additional projects in the future
- The LSA provides Juno a non-exclusive license to Oxford’s LentiVector platform for its application in CAR-T and TCR-T programs in oncology and other indications and additionally enters into a 5yrs. clinical supply agreement that can be extended further
Click here to read full press release/ article | Ref: Oxford Biomedica | Image: Juno Therapeutics
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com